Renascience

Renascience Debt Growth

The Year-over-Year Debt Growth of Renascience (4889.T) as of Nov 19, 2026 is -100.00 %. In the previous year, Year-over-Year Debt Growth was 15.02 % — a change of -765.81% (lower).

Debt Growth

-100.00 %

YoY

-765.81%

Last updated:

Year-over-Year Debt Growth of Renascience is 2025 -100.00 % . Year-over-Year Debt Growth of Renascience was 2024 15.02 % . It decreases by -765.81% lower compared to the previous year.

The Renascience Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2021
25.17 JPY
Jan 1, 2022
-58.11 JPY
Jan 1, 2023
55.40 JPY
Jan 1, 2024
15.02 JPY
Jan 1, 2025
-100.00 JPY
The Renascience Debt Growth history
YEARDebt GrowthYoY
-100.00 %-765.81%
15.02 %-72.89%
55.40 %-195.33%
-58.11 %-330.88%
25.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Year-over-Year Debt Growth of Renascience is -100.00 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Renascience since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Renascience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Renascience

All Key Metrics — Renascience